Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy.

Abstract

Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma. Therefore, to increase its response rate is of great interest to dermatologists. Recent reports suggested that, since CD8+ T cells after the administration of ICIs increase the RANKL expression to induce an immunosuppressive tumor microenvironment in melanoma, denosumab might enhance the anti-tumor effects of immune checkpoint inhibitors, such as nivolumab and ipilimumab. In this report, we present a case of multiple metastatic melanoma with nivolumab, ipilimumab plus denosumab combined therapy.

• Authors: Saaya Yoshida, Taku Fujimura, Yumi Kambayashi, Ryo Amagai, Akira Hashimoto, Setsuya Aiba
• Journal: Case reports in oncology (Case Rep Oncol) 2019 Sep-Dec Vol. 12 Issue 3 Pg. 829-833 ISSN: 1662-6575 [Print] Switzerland
• PMID: 31762756 (Publication Type: Case Reports)
• Copyright: Copyright © 2019 by S. Karger AG, Basel.